Your browser doesn't support javascript.
loading
Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong, Hyehyun; Jeong, Jae Ho; Kim, Jeong Eun; Ahn, Jin-Hee; Jung, Kyung Hae; Kim, Sung-Bae.
Afiliación
  • Jeong H; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Jeong JH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Kim JE; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Ahn JH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Jung KH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Kim SB; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Cancer Res Treat ; 54(2): 469-477, 2022 Apr.
Article en En | MEDLINE | ID: mdl-34176251
PURPOSE: In hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer (HR+ HER2-MBC), the mainstay treatment options include cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and everolimus (EVE) in combination with endocrine treatment. This study aims to compare the outcomes of the following treatment sequences: CDK4/6i followed by EVE and EVE followed by CDK4/6i. MATERIALS AND METHODS: Data from HR+ HER2- MBC patients treated between January 2014 and November 2020 with both CDK4/6i and EVE were retrospectively analyzed. RESULTS: Among the 88 patients included in the study, 51 received CDK4/6i before EVE (C→E group), and 37 received EVE before CDK4/6i (E→C group) with endocrine treatment. More patients in the E→C group had endocrine resistance (13.7% vs. 40.5%), experienced palliative chemotherapy (7.8% vs. 40.5%), and were heavily treated (treated as ≥ 3rd line, 5.9% vs. 40.5%). Median overall survival was 46.8 months in the C→E group and 38.9 months in the E→C group (p=0.151). Median composite progression-free survival (PFS), defined as the time from the start of the preceding regimen to disease progression on the following regimen or death, was 24.8 months in the C→E group vs. 21.8 months in the E→C group (p=0.681). Median PFS2/PFS1 ratio did not differ significantly between groups (0.5 in the C→E group, 0.6 in the E→C group; p=0.775). Ten patients (11.4%) discontinued EVE, and two patients (2.3%) discontinued CDK4/6i during treatment. CONCLUSION: Although the CDK4/6i-based regimen should be considered as an earlier line of treatment, CDK4/6i- and EVE-based treatments can be valid options in circumstances where the other treatment had been already given.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Everolimus Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cancer Res Treat Año: 2022 Tipo del documento: Article Pais de publicación: Corea del Sur
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Everolimus Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cancer Res Treat Año: 2022 Tipo del documento: Article Pais de publicación: Corea del Sur